All In Biotech

Drug Trial Radar · NCT00140582

Primary Rituximab and Maintenance

Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy With Rituximab (MabThera®) After Induction of Response With Chemotherapy Plus Rituximab in Comparison With no Maintenance Therapy

Last checked: Nov 20, 2026Latest source record: Mar 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,217 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,217

Actual

Start

Dec 2004

Primary completion

May 2007

Study completion Dec 2016

Sponsor

Lead sponsor
Lymphoma Study AssociationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
HOVON - Dutch Haemato-Oncology Association; German Low Grade Lymphoma Study Group; Australasian Leukaemia and Lymphoma Group; Institute of Cancer Research, United Kingdom
First posted
Sep 1, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

* Objectives * Primary objective: To evaluate in patients with advanced follicular lymphoma the benefit of maintenance therapy with rituximab after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy * Secondary objective: To evaluate response rates, event driven survival endpoints (EFS, PFS, OS) and quality of life of four different chemotherapy regimens combined with rituximab, with or without maintenance with rituximab, for first line treatment of advanced stage follicular lymphoma. * Study Design This is an international open-label, multicentre, randomized study with two treatment phases. In the induction phase patients have to respond to 1st line induction treatment in order to be eligible for randomization to the second phase of maintenance treatment or observation. After the maintenance period patients will be included in the follow up phase for 3 years.

Conditions

  • Follicular Lymphoma

Interventions

  • RituximabDrug

    rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: number of event observed driven : 344 events or 10 years

Locations

24 sites in 12 countries. Site status is shown where the registry gives one.

  • Fundaleu Hospital

    Buenos Aires, Argentina

  • Australian Leukemia and Lymphoma Group

    Melbourne, Australia

  • Université de Gent

    Ghent, Belgium

  • Groupe d'Etude des Lymphomes de l'adulte

    Mont-Godinne, Belgium

  • Hospital Samaritano

    São Paulo, Brazil

  • Fundación Santafé de Bogotá

    Bogotá, Colombia

  • Amtssygehuset i Herlev

    Herlev, Denmark

  • Polyclinique Bordeaux Nord

    Bordeaux, France

  • Hôpital Henri Mondor

    Créteil, France

  • Hématologie CHU de Lille

    Lille, France

  • Centre Léon Bérard

    Lyon, France

  • Institut Curie

    Paris, France

  • Hôpital Saint Louis

    Paris, France

  • Hématologie Adultes - Hôpital Necker

    Paris, France

  • Service d'Hématologie - Centre Hospitalier Lyon-Sud

    Pierre-Bénite, France

  • Centre Hospitalier Robert Debré

    Reims, France

  • Centre Henri Becquerel

    Rouen, France

  • Hématologie CHU Purpan

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

  • HOVON

    Utrecht, Netherlands

  • Australia New Zealand Leukemia Lymphoma Group

    Auckland, New Zealand

  • Instituo Nacional de Enfermedades Neoplasicas

    Lima, Peru

  • Hospital Clinic Barcelona

    Barcelona, Spain

  • King Chulalongkorn Memorial Hospital

    Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.